Company Overview and News

1
D-Street Buzz: Bank, oil gas stocks rally led by Bank of Baroda, HPCL; RIL hits record high, Adani Power spikes 12%

2018-07-12 moneycontrol
The Indian benchmark indices are trading on a positive note this Thursday morning with the Nifty jumping 78 points and is trading above the 11,000 mark while the Sensex is trading higher by 257 points at 36,522, reaching a new record high.
500408 500325 533096 HCTHY 512599 532480 500696 532281 EROSMEDIA GODREJCP CHENNPETRO RLNIY SBAZ ANNRY AXB ALBK YYBKY 532424 AXBA HCLTECH 500180 KOTAKBANK ADANIENT RELIANCE HINDUNILVR 533155 JUBLFOOD 532215 GDRJY 532187 532461 AXISBANK RIGD JBLWY HDFCBANK 500110 YESBANK UBNC INDUSINDBK KMBKY 533261 IBN 532648 AXBKY ICICIBANK PNJZY HDB 532174 TATAELXSI PNB ADANIPOWER 500247

4
HPCL, BPCL, IOC fall 6-8% after Brent crude oil prices spike over $77/bbl

2018-06-27 moneycontrol
The share prices of oil marketing companies ended sharply lower on Wednesday after crude oil prices jumped over $77 a barrel.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104 500110 CHENNPETRO

3
CPCL gets nod for taking up Nagapattinam refinery expansion

2018-05-10 moneycontrol
Chennai Petroleum Corporation has been given in-principle approval for its Rs 27,000 crore refinery expansion project in Tamil Nadu, a top official said today.
IOC 530965 500110 CHENNPETRO

0
IOC to invest Rs 1.4 lakh crore to double refining capacity

2018-03-31 moneycontrol
India's biggest oil firm IOC today said it plans to invest about Rs 1.43 lakh crore to nearly double its oil refining capacity to 150 million tonnes and boost petrochemical production by 2030.
500110 CHENNPETRO

3
Indian Oil to invest Rs1.4 trillion to double refining capacity

2018-03-31 livemint
New Delhi: India’s biggest oil firm IOC on Saturday said it plans to invest about Rs1.43 trillion to nearly double its oil refining capacity to 150 million tonnes and boost petrochemical production by 2030.
IOC 530965 500110 CHENNPETRO

35
Market Update: PSU Bank index up 1% led by SBI; CNX IT drags as Wipro falls 2%; GAIL, HPCL shed up to 4%

2018-03-26 moneycontrol
The Indian equity market was trading almost flat on Monday morning with the Nifty trading lower by 9 points, trading below the 10,000 mark at 9988 while the Sensex was up 25 points or 0.08 percent.
IOC CAPF TCHQY 532755 CADILAHC 532321 BJJQY GAILF 500570 CHENNPETRO SBAZ PTC YYBKY 530965 TECHM BAJFINANCE TATASTEEL TATLY GAMMONIND GAILY 509550 TCS 523204 532938 IDBI 533155 TTNQY JUBLFOOD ABAN 500470 532540 532187 532461 JBLWY SKFINDIA TATAMOTORS 500472 500110 500034 YESBANK UBNC 500116 INDUSINDBK IBN 532648 532524 CDLYY ICICIBANK TTST PNJZY 532174 PNB TTM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...